MiMedx Group, Inc. MDXG 深 沪
已收盘 02-06 16:00:00 美东时间
5.15
+0.120
+2.39%
华盛通- 最 高5.19
- 今 开5.02
- 成交量 87.63万股
- 最 低 4.935
- 昨 收 5.03
- 总市值 7.63亿
- 52周最高 8.4995
- 市盈率 静 18.10
- 换手率 0.59%
- 52周最低 4.89
- 委 比 11.79%
- 总股本 1.48亿
- 历史最高 18.25
- 量 比 0.70
- 振 幅 5.07%
- 历史最低 0.83
- 每 手 1
- 风险率 0.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MiMedx Group Strikes Deal With Summit Products For Distribution Of Hydrelix, NovaForm, and G4Derm Plus
MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced it has entered into an exclusive agreement with Summit Products Group ("Summit") to distribute three innovative, 510(k) cleared products that
02-04 23:30
MiMedx Group Signs Exclusive Distribution Agreement with Summit Products Group
MiMedx Group Signs Exclusive Distribution Agreement with Summit Products Group MiMedx Group Inc. announced it has entered into an exclusive distribution agreement with Summit Products Group for three 510(k) cleared products: Hydrelix, NovaForm, and G4Derm Plus. The agreement expands MiMedx’s surgica
02-04 23:27
MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
MiMedx Group announced the 15th anniversary of its EPIFIX and AMNIOFIX placental allografts, used for wound care and surgical recovery. With over 100 clinical studies, including seven randomized controlled trials, these products are recognized as the industry’s most studied. MIMEDX has advanced wound care and surgical recovery, becoming a leader in the field. The company’s vision is to be a global leader in healing solutions through innovation.
02-02 13:00
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
Lake Street Maintains Buy on MiMedx Group, Lowers Price Target to $10
Lake Street analyst Brooks O'Neil maintains MiMedx Group (NASDAQ:MDXG) with a Buy and lowers the price target from $12 to $10.
01-21 03:49
Organogenesis, MiMedx among decliners as Medicare to pull skin substitute LCDs
Organogenesis (ORGO) and MiMedx (MDXG) traded lower on Friday after the Centers for Medicare & Medicaid Services (CMS) announced the withdrawal of final Local Coverage Determinations (LCDs) related to...
2025-12-26 23:41
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel
MiMedx Group announced an exclusive agreement with Regen Lab USA LLC to distribute RegenKit®-Wound Gel in the U.S. This autologous PRP and ATS wound gel is FDA-approved, CMS-covered, and effective for treating chronic wounds, particularly diabetic ones. The product enhances MiMedx's Advanced Wound Care portfolio and aligns with their mission to provide innovative healing solutions. The company expects the addition to strengthen its competitive po...
2025-12-22 14:43
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
MIMEDX Group Releases Interim Results From Its Campaign Trial, Showing That Its EPIEFFECT Significantly Outperformed Standard Care In Treating Nonhealing Diabetic Foot Ulcers
MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the publication of interim results from its CAMPAIGN trial, a randomized controlled trial ("RCT") designed to evaluate the performance of the
2025-11-13 21:11
MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial
MiMedx announced interim results from its CAMPAIGN trial, showing EPIEFFECT's superiority over standard wound treatment in managing diabetic foot ulcers. Published in *International Journal of Tissue Repair*, the study, based on 71 patients, demonstrated a 98.5% posterior probability of EPIEFFECT's effectiveness. The Company also presented at TRES with an 88-patient sample, further supporting EPIEFFECT's performance. MIMEDX aims to leverage these...
2025-11-13 13:00
